Navigation Links
ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinson's Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinson's Brain

KIRKLAND, Wash., Feb 26 /PRNewswire/ -- ProteoTech Inc. announced today that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Disease Research. In collaboration with Avid Radiopharmaceuticals Inc. (Philadelphia, PA), ProteoTech scientists will utilize ProteoTech's small molecule platform drug technology to develop new imaging agents that will allow doctors to use PET imaging to identify and determine the extent of alpha-synuclein accumulation in the living human brain. Alpha-synuclein is a major protein identified in Lewy bodies in the Parkinson's disease brain, and its accumulation in brain is believed to be important in the motor dysfunction observed in Parkinson's patients. The one-and-a-half year project entitled "18-F-labeled Alpha-Synuclein Ligands for PET Imaging of Lewy Bodies" will be led by Dr. Alan Snow, Chairman, President & Chief Scientific Officer of ProteoTech, and Dr. Franz Hefti, Chief Scientific Officer of Avid Radiopharmaceuticals Inc.


ProteoTech is currently in its 4th year of a LEAPS award funded by The Michael J. Fox Foundation for Parkinson's Disease Research to develop a new small molecule targeting alpha-synuclein in Parkinson's brain. ProteoTech's Synuclere(TM) has been demonstrated to inhibit alpha-synuclein aggregation in the brains of genetically engineered mice that develop motor dysfunction, when alpha-synuclein deposits aggregate and accumulate in brain. The LEAPS award consortium led by Dr. Alan Snow of ProteoTech includes research teams from University of California-San Diego, Boston University, Boston College and Medchem Source Inc.

About ProteoTech: ProteoTech is a private drug development Company founded in 1996 that is a world-leader in therapeutics targeting amyloid diseases. With over 175 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1 for the treatment of mild-to-moderate Alzheimer's disease. The Company is in late-stage pre-clinical development with Synuclere(TM) for the treatment of Parkinson's disease, and Systebryl(TM) for the treatment of Systemic Amyloidosis. ProteoTech is also in late stage pre-clinical development for a novel small peptide called PeptiClere(TM) as a nasal spray for the treatment of Alzheimer's disease. Lastly, ProteoTech is developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes. For further information, please visit the Company's website at or contact us at

SOURCE ProteoTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ProteoTech to Present at Rodman & Renshaws 10th Annual Healthcare Conference
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... For many X-rays taken at hospitals, doctors’ ... by the radiologist. The marking utensils are so small, however, they are difficult ... way to alleviate this problem. , He developed the patent-pending MARK N SHOW ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
(Date:12/1/2015)... Burlington, MA (PRWEB) , ... December 01, 2015 , ... ... the release of Clarity, the latest addition to the devices for sale in the ... technologies, 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform ...
(Date:12/1/2015)... ... , ... XTC Semifinals 2016 - CES, Las Vegas, Nevada - ... CES 2016, the world’s largest Consumer Electronic Show, where they will present to a ... of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among many other top ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Nurotron Biotechnology Co., ... its largest order to date. , The order will be from the China ... Venus Cochlear Implant System is an effective solution for children and adults suffering from ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... ) has ... Systems/Personal Emergency Response System (PERS) Market by Type, ... report to their offering. --> ... "Medical Alert Systems/Personal Emergency Response System (PERS) ... - Global Forecas" report to their offering. ...
(Date:12/1/2015)... -- --> --> ... (NKI-AVL), among the world,s largest and most prestigious ... Icon™, the company,s latest generation stereotactic radiosurgery system ... --> With the option to use ... Knife Icon offers greatly enhanced flexibility in how ...
(Date:12/1/2015)... Colo. , Dec. 1, 2015 Ampio ... New York Stock Exchange has established January 5, 2016 as ... its stockholders of the shares of Common Stock of ... (1) share of Aytu common stock for every five ... the record date, December 1, 2015. The distribution date will ...
Breaking Medicine Technology: